A Drug That Erases an Immune Protein Entirely Enters Rheumatoid Arthritis Trials Without JAK Inhibitor Safety Warnings
· techtimes.com · popularity 16/100 · 0 similar stories today · Chronic Conditions (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Evommune licensed a drug that erases an immune protein to bypass JAK inhibitor warnings; Caldera added a TL1A bispecific from the same Chinese partner.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 17.